AzTrials
AzTrials

Persistent Atrial FibrillationVEMAPULSENCT06383975

VEin of MArshall Ethanolization Vs Extended Pulmonary Vein PULSEd Field Ablation After Failed PVI for Persistent AF

A study testing Pulsed field ablation with posterior wall isolation and Radiofrequency ablation and vein of Marshall ethanolization in people with Persistent Atrial Fibrillation, run by Sebastien Knecht at 1 site in Belgium.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The goal of this clinical trial is to compare two ablation techniques to treat patients with persistent atrial fibrillation (irregular and often very rapid heart rhythm). An ablation is a procedure during which some scars are made on the inside of the heart to break up the electrical signals that cause the irregular… Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Persistent Atrial Fibrillation
What is being tested?
Pulsed field ablation with posterior wall isolation and Radiofrequency ablation and vein of Marshall ethanolization
Could I receive a placebo?
No, everyone receives an active treatment
How many people
100 participants
Where
1 siteBelgium
Study dates
15 May 2024to 30 Apr 2027
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Symptomatic persistent atrial fibrillation (AF) despite a first PVI. Persistent AF is defined as the presence of AF lasting ≥7 days (i.e. in case of new onset AF one has to wait for 7 days)

Who cannot join

  • Persistent AF lasting ≥ 12 months
  • Advanced valvular heart disease
  • Left atrial (LA) volume >150mL
  • LA diameter (PS-LAX) >60mm
  • Septal wall diameter >15mm
  • Life expectancy <1 year
  • Weight >150 kg
  • Any contra indication to catheter ablation

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Belgium1 site, 1 recruiting
  • AZ Sint-Jan Brugge AV

    Bruges, 8000

    Emma Christiaen, emma.christiaen@azsintjan.be

    Sébastien Knecht, MD, PhD

    Recruiting

Other trials in Belgium

About this study

Official title: Comparison Between VEin of MArshall Ethanol Infusion Versus Extended Pulmonary Vein PULSEd Field Ablation After Failed Pulmonary Vein Isolation in Patients with Persistent Atrial Fibrillation

The goal of this clinical trial is to compare two ablation techniques to treat patients with persistent atrial fibrillation (irregular and often very rapid heart rhythm). An ablation is a procedure during which some scars are made on the inside of the heart to break up the electrical signals that cause the irregular heartbeat. In this trial researchers will compare a new technique, which uses tiny electric shocks to make the scars, to the standard technique, which uses heat.

The main question the trial aims to answer is:

Read more
  • Does the new technique work as well as the standard technique to prevent the irregular heartbeat from returning within one year of the procedure?

Participants will:

  • Undergo an ablation with either the new or the standard technique
  • Visit the hospital 1, 3, 6, 9 and 12 months after the procedure for a check-up
  • Wear a device to register their heart rhythm for 24 hours before the 3 month visit and for 72 hours before the 6, 9 and 12 month visit
  • Record their heart rhythm at home every week
  • Complete a questionnaire 3, 6, 9 and 12 months after the procedure
Read the detailed description

Background

Pulmonary vein isolation (PVI) remains the cornerstone of catheter ablation for the treatment of atrial fibrillation (AF). However, in patients with persistent AF, recurrence occurs in 20% to 50% of the patients. These patients often need additional ablation beyond PVI in the index procedure or in a redo procedure. During redo procedures, optimal management of AF has not been validated yet. Different strategies are used but without strong scientific background and without uniformity.

In the case of PV reconnection, PV re-isolation alone seems to be the gold standard in healthy atria, but with moderate success in patients with dilated left atrium or scar zones.

Different recent studies show a potential impact of posterior wall isolation; however with discordant results. This could be in part related to low rate of durable posterior wall isolation and also due to potential risk of esophageal fistula limiting the use of RF ablation at the posterior wall. The use of pulsed field energy could improve lesion durability and avoid any risk of fistula.

On the other hand, ethanol infusion in the vein of Marshal has also been shown to improve the success rate of persistent AF ablation but requires significant experience and may be time-consuming.

Rationale

Currently, there are no clear ablation endpoints in the case of AF recurrence post PVI. Especially for patients with persistent AF since substrate ablation beyond PVI does not seem to improve the success rate during a first procedure. However, this could be related to inappropriate patient selection. Indeed, PVI-resistant patients present those with worst prognosis with respect to AF recurrence. Additionally, when durable PVI is observed following recurrence in patients with persistent AF, case ablation beyond PVI seems reasonable and necessary.

The aim of this trial is to compare two strategies with clear endpoints, to avoid potential bias. The gold standard, PVI, is also respected in both groups In one group, PFA re-isolation of PVs and of the posterior wall has the advantage of a clear straight forward approach, with short-lasting procedures and which does not require high level technical skills.

In the second group, radiofrequency guided PV re-isolation will be performed in combination with mitral, aided by vein of Marshall ethanol infusion, and dome lines until bidirectional block. A Vein of Marshall is present in ~90% of the patients and strongly facilitates block at the mitral line (almost 100%) while a dome transection reduces the risk of further left atrial tachyarrhythmia.

Hypothesis

The hypothesis of this study is that the efficacy of a straightforward strategy of PV re-isolation (if necessary) and additional posterior wall isolation using the PFA FARAPULSETM catheter is comparable to that of a more complex and time consuming RF strategy aiming at vein of Marshall ethanol infusion and linear lesions at the roof and at the mitral line.

Design

This is a prospective, randomized (1:1), open label, blinded endpoint study (PROBE). Eligible subjects, who sign the study informed consent form, with persistent AF will be randomized into one of two study arms. In the pulsed field ablation (PFA) arm, patients will be treated using the FARAPULSETM catheter, aiming at pulmonary vein (PV) re-isolation (if necessary) and isolation of the posterior wall. In the radiofrequency (RF) group, patients will receive ethanol infusion in the vein of Marshall, followed by re-isolation of the PV (if necessary), dome and mitral lines with aim at bidirectional block.

Being tested
Pulsed field ablation with posterior wall isolation, Radiofrequency ablation and vein of Marshall ethanolization
Medical subject headings
Atrial Fibrillation

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Pulsed field ablation with posterior wall isolationProcedure or surgery

    Extended pulmonary vein isolation including posterior wall isolation using pulsed field ablation

  • Radiofrequency ablation and vein of Marshall ethanolizationProcedure or surgery

    Radiofrequency pulmonary vein re-isolation (when necessary), vein of Marshall ethanol infusion with roof and mitral lines

Study groups in NCT06383975
Study groupRoleWhat they receive
Pulsed field ablation with posterior wall isolationExperimentalNot described
Receives: Procedure: Pulsed field ablation with posterior wall isolation
Radiofrequency ablation and vein of Marshall ethanolizationActive comparatorNot described
Receives: Procedure: Radiofrequency ablation and vein of Marshall ethanolization

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Atrial tachyarrhythmia recurrence within 12 months

    Percentage of patients with any atrial tachyarrhythmia recurrence (> 30 sec) from 2 months (blanking period) to 12 months after the ablation procedure

    Measured: 2-12 months

Secondary outcomes (7)
  1. Safety and procedural related adverse event

    Occurrence of vascular complications, tamponade, transient ischemic attack/stroke and other adverse events during and after the procedure, and within 12 months post procedure

    Measured: During procedure-12 months

  2. Duration of the ablation procedure

    Duration of the ablation procedure in both groups

    Measured: During procedure

  3. Fluoroscopy time

    Fluoroscopy time

    Measured: During procedure

  4. Fluoroscopy dose

    Fluoroscopy dose during the procedure

    Measured: During procedure

  5. Effect of the procedure on quality of life

    Results of the 36-Item Short Form Survey Instrument (SF-36) before and 3, 6, 9 and 12 months post procedure. The scores range from 0 to 100. A higher score corresponds with a better outcome.

    Measured: 3, 6, 9, 12 months

  6. Incidence of repeat ablation

    Percentage of patients who need another ablation within 12 months post procedure

    Measured: 12 months

  7. Unscheduled visits and hospitalization

    Number of unscheduled visits and hospitalization within 12 months post procedure

    Measured: 12 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted25 Apr 2024
  2. Study start15 May 2024
  3. Primary completion30 Apr 2027 (estimated)
  4. Study completion30 Apr 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Participant
Enrolment
100 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06383975
Sponsor's protocol ID
CIV-24-01-045634
Acronym
VEMAPULSE
Status last verified
Oct 2024
First submitted
16 Apr 2024
Last updated
9 Oct 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Pulsed field ablation with posterior wall isolation and Radiofrequency ablation and vein of Marshall ethanolization in people with Persistent Atrial Fibrillation, run by Sebastien Knecht at 1 site in Belgium.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 9 Oct 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Emma Christiaen (003250453293, emma.christiaen@azsintjan.be), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Atrial tachyarrhythmia recurrence within 12 months (time frame: 2-12 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Oct 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in